Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Evogene Reports Second Quarter and First Half 2026 Financial Results

      Evogene Logo

      News provided by

      Evogene

      Aug 18, 2026, 08:04 ET

      Share this article

      Share this article


      • Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product development programs
      • Cash burn expected to decline to approximately $8.5–$9.5 million in 2026, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024 
      • Second-quarter net loss was reduced to approximately $1.8 million, compared with approximately $4.7 million in the second quarter of 2025 and approximately $6.0 million in the second quarter of 2024
      • Six active drug development collaborations established with biotechnology companies and leading academic institutions
      • Virtual chemical space expanded to approximately 110 billion molecules, supported by advanced AI models and autonomous AI Agents

      REHOVOT, Israel, Aug. 18, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first half of 2026 and second quarter ended June 30, 2026, and provided an update on its strategic and operational progress.

      Strategic Transformation Delivering Measurable Progress

      Over the past 18 months, Evogene has undergone a significant strategic transformation, focused on establishing the Company as a lean, AI-driven leader in computational chemistry for pharmaceutical and crop protection applications.

      As part of this transformation, Evogene has significantly streamlined its operations, reduced its workforce from 117 employees in December 2024 to 38 in August 2026, substantially reduced operating expenses, and realigned its portfolio toward activities with significant commercial potential.

      The Company expects full-year 2026 cash usage to be approximately $8.5 million to $9.5 million, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024, with further reductions targeted for 2027.

      Since the beginning of 2025, Evogene has also raised approximately $11.1 million in new capital, strengthening its financial position and providing additional resources to execute its strategic priorities.

      Continued Commercial and Technological Momentum

      Evogene's Pharma division continues to demonstrate strong momentum. Since the beginning of 2026, the Company has entered four new drug development collaborations, bringing the total number of active collaborations to six with biotechnology companies and leading academic institutions.

      Two of these programs have already completed the initial Hit Identification stage of Evogene's ChemPass AI™ computational discovery process, with validation results exceeding partner expectations. Evogene is currently advancing these programs toward subsequent stages of development.

      Across these programs, Evogene retains significant commercial rights to the resulting discoveries, providing the potential for future revenue generation as programs progress through development and toward commercialization.

      In parallel, Evogene is advancing its internal drug discovery program. The program has successfully completed the Hit-to-Lead stage and progressed into Lead Optimization, where the Company is generating proprietary molecules with the potential to serve as candidates for future preclinical development.

      In Agriculture, Evogene continues to advance its crop protection program targeting Septoria, a major fungal disease. The program is approaching completion of the Lead Optimization stage, with synthesized molecules currently undergoing advanced biological testing ahead of greenhouse and field trials.

      Major Expansion of ChemPass AI™

      Evogene continues to substantially expand the capabilities of its core computational platform, ChemPass AI™.

      Following the Company's second agreement with Google Cloud, In June Evogene has integrated advanced AI Agents into its computational workflow. These autonomous systems are designed to automate complex research tasks that traditionally required weeks or months of highly specialized scientific work, enabling the company to perform these activities in a matter of minutes.

      In July, Evogene has also expanded its portfolio of predictive AI models. Among these is the recently announced Antifungal Potency Predictor (APP), designed to predict the activity of small molecules against fungal pathogens and provide an additional layer of biological prediction beyond target-level interaction.

      In addition, this month Evogene has expanded its virtual chemical space from approximately 36 billion to approximately 110 billion molecules, significantly increasing the scope of chemical molecules that can be explored by its computational discovery platform.

      Portfolio Optimization and Focus on Core Opportunities

      Consistent with its revised strategy, Evogene has substantially reduced or transitioned its non-core activities.

      Lavie Bio is no longer operational following the sale of the majority of its assets to ICL. Under the transaction, two additional payments remain due to Lavie Bio and Evogene, with the first received in July 2026 and the second expected in July 2027. In addition, Lavie Bio distributed a $4.25 million dividend to its shareholders during the second quarter, of which Evogene received approximately $2.9 million. Beginning in the second quarter of 2025, Lavie Bio's results of operations have been presented separately as discontinued operations.

      Biomica, following the successful completion of its Phase 1 clinical trial and the licensing of its lead oncology candidate BMC128 to Lishan Pharmaceuticals, is no longer conducting ongoing operations. During the second quarter, Biomica completed a $2.7 million dividend distribution to shareholders, of which Evogene received approximately $1.35 million. Beginning in the second quarter of 2026, Biomica's results are presented as discontinued operations in the consolidated statements of profit or loss.

      Casterra has significantly reduced and realigned its activities and is now focused exclusively on Brazil.

      Management Commentary

      "We have fundamentally transformed Evogene over the past 18 months," said Ofer Haviv, President and Chief Executive Officer of Evogene. "We have moved from a broad portfolio of activities to a highly focused organization centered on our AI-driven computational chemistry capabilities, while substantially reducing our cost structure and cash requirements."

      "At the same time, we are seeing meaningful validation of our technology through new collaborations, progress in our internal drug discovery programs, and major advances in ChemPass AI. The expansion of our virtual chemical space to approximately 110 billion molecules and the integration of autonomous AI Agents represent important steps forward in our ability to discover novel molecules faster and more efficiently."

      "Looking ahead, our priorities are clear: advance our existing pharmaceutical and agricultural programs, establish additional collaborations with leading biotechnology and pharmaceutical companies, advance our internal high-value programs, pursue strategic partnerships in agriculture, and continue to strengthen our computational platform."

      Nir Nimrodi, Chairman of Evogene's Board of Directors, added: "The second quarter reflects the significant transformation we have executed across Evogene. We have streamlined the organization, reduced our cash requirements, optimized our portfolio, and concentrated our resources on opportunities with substantial commercial potential."

      "The combination of a significantly lower cost base, a stronger financial foundation, growing commercial validation, and rapid technological progress provides Evogene with a substantially more focused platform from which to execute its strategy and create long-term shareholder value."

      First Half 2026 and Second Quarter Ended June 30, 2026, Financial Highlights

      • Cash Position - As of June 30, 2026, Evogene held consolidated cash and cash equivalents of approximately $9.3 million. Consolidated cash usage during the second quarter of 2026 was approximately $2.1 million.
      • Revenues for the first half of 2026 totaled approximately $0.7 million, compared to approximately $2.9 million in the same period of 2025, representing a decrease of approximately $2.2 million. The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2.0 million. Revenues for the second quarter of 2026 were approximately $0.3 million, representing a slight decrease compared to approximately $0.5 million in the same period last year, mainly attributable to the conclusion of AgPlenus' agreement with Bayer in May 2026.
      • Research and development expenses, net of non-refundable grants, for the first half of 2026 were approximately $2.9 million, compared to approximately $3.5 million in the corresponding period of 2025, representing a decrease of approximately $0.6 million. The decrease is mainly attributable to lower R&D expenses in Casterra and AgPlenus, which were partially shifted to Evogene as the Company redirected its R&D efforts toward activities that are core to, and support the execution of, its new strategy.  The decrease in R&D expenses was partially offset by the impact of exchange rate fluctuations between the U.S. dollar and the NIS of approximately $0.4 million. For the second quarter of 2026, R&D expenses were approximately $1.4 million, down from $1.7 million in the same period of 2025. This decrease is mainly attributable to decreased expenses in Casterra, partially offset by increased expenses in Evogene as mentioned above. In addition, the decrease was partially offset by the impact of exchange rate fluctuations between the U.S. dollar and the NIS of approximately $0.2 million.
      • Sales and marketing expenses for the first half of 2026 and 2025 were approximately $0.7 million, with no material change between the periods. Sales and marketing expenses for the second quarter of 2026 were approximately $0.3 million, a slight decrease from approximately $0.4 million in the second quarter of 2025.
      • General and administrative expenses for the first half of 2026 decreased slightly to approximately $2.0 million, compared to approximately $2.1 million in the corresponding period of 2025. The decrease in G&A expenses attributable to Evogene and its subsidiaries was substantially offset primarily by the impact of transaction costs related to the warrant inducement transaction and other legal expenses, totaling approximately $0.2 million, as well as by exchange rate fluctuations between the U.S. dollar and the NIS of approximately $0.2 million. General and administrative expenses for the second quarter of 2026 slightly decreased to approximately $0.9 million compared to approximately $1.0 million in the same period of the previous year.
      • Financing expenses, net, for the first half of 2026 were approximately $1.7 million, compared to financing income, net, of approximately $0.8 million in the corresponding period of 2025.

      This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first half of 2026. In addition, the Company recorded financing income of approximately $2.1 million related to the revaluation of warrants liability as of June 30, 2026. Financing income, net for the second quarter of 2026 was approximately $972 thousand, compared to financing expense, net of approximately $333 thousand in the same period of the previous year. The decrease is mainly associated with the warrants' accounting treatment as mentioned above.

      • Loss from discontinued operations, net, for the first half of 2026 was approximately $0.5 million, compared to a loss from discontinued operations, net, of approximately $3.6 million in the corresponding period of 2025. For the second quarter of 2026, the loss from discontinued operations was approximately $0.2 million, compared to approximately $1.7 million in the second quarter of the previous year. These amounts primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expense levels have decreased significantly.
      • Net loss for the first half of each of 2026 and 2025 was approximately $7.7 million, with no material change between the periods. The net loss for the second quarter of 2026 was approximately $1.8 million, compared to approximately $4.7 million in the same period last year. The $2.9 million decrease in net loss was primarily due to decreased operating expenses, decreased loss from discontinued operations and increased financing income, net as mentioned above.

      About Evogene Ltd.

      Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

      For more information, please visit www.evogene.com. 

      Forward-Looking Statements

      This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.

      Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between Israel and the United States, on the one hand, and Iran and its proxy  terrorist groups, Hamas, Hezbollah, and, intermittently, the Houthis in Yemen, on the other hand, (and any destabilizations in Israel, neighboring territories or the Middle East region resulting from those wars; Evogene's and its subsidiaries' reliance on third parties to conduct certain activities, such as field-trials and pre-clinical studies, which could cause significant delays in the conduct of those activities; the potential impact of a change of control of Evogene's board of directors due to the actions of dissident shareholders; as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Evogene's actual results to differ from those reflected in its forward-looking statements, please see "Item 3.D. Risk Factors" in Evogene's Annual Report on Form 20-F for the year ended December 31, 2025, and its subsequent reports filed with or furnished to the U.S. Securities and Exchange Commission and Israeli Securities Authority. You should not place undue reliance on any forward-looking statements included in this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except to the extent required by applicable law.

      Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

      Contact: 
      [email protected] 
      Tel: +972-8-9311901

      CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
      U.S. dollars in thousands








      June 30,


      December 31,



      2026


      2025



      Unaudited



      ASSETS





      CURRENT ASSETS:





      Cash and cash equivalents


      $                        9,316


      $                     12,956

      Restricted cash


      35


      32

      Trade receivables


      384


      317

      Other receivables and prepaid expenses


      1,026


      1,565

      Deferred expenses related to issuance of warrants


      -


      551

      Inventories


      93


      210








      10,854


      15,631

      LONG-TERM ASSETS:





      Long-term deposits and other receivables


      531


      571

      Investment accounted for using the equity method


      -


      43

      Deferred expenses related to issuance of warrants


      -


      1,165

      Right-of-use-assets


      1,558


      1,824

      Property, plant and equipment, net


      497


      812








      2,586


      4,415






      TOTAL ASSETS


      $                     13,440


      $                     20,046






      LIABILITIES AND EQUITY










      CURRENT LIABILITIES:





      Trade payables


      $                           394


      $                       639

      Employees and payroll accruals


      911


      861

      Lease liabilities


      668


      716

      Liabilities in respect of government grants


      89


      56

      Deferred revenues and other advances


      21


      17

      Warrants and pre-funded warrants liability


      659


      706

      Other payables


      302


      449








      3,044


      3,444

      LONG-TERM LIABILITIES:





      Lease  liabilities


      1,433


      1,482

      Liabilities in respect of government grants


      3,130


      3,073

      Deferred revenues and other advances


      65


      72








      4,628


      4,627






      TOTAL LIABILITIES


      $                      7,672


      $                     8,071






      CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
      U.S. dollars in thousands






      SHAREHOLDERS' EQUITY:





      Ordinary shares of NIS 0.2 par value:

      Authorized – 30,000,000 ordinary shares; Issued and
      outstanding – 13,535,843 ordinary shares on June 30,
      2026 and 8,718,193 ordinary shares on December 31,
      2025


      804


      488

      Share premium and other capital reserves


      286,100


      281,986

      Accumulated deficit


      (290,194)


      (282,556)






      Equity attributable to equity holders of the Company


      (3,290)


      (82)






      Non-controlling interests


      9,058


      12,057






      TOTAL EQUITY


      5,768


      11,975






      TOTAL LIABILITIES AND EQUITY


      $            13,440


      $            20,046











      CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS
      U.S. dollars in thousands (except share and per share amounts)




       

      Six months ended
      June 30,


       

      Three months ended
      June 30,


      Year ended
      December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)



      Unaudited


      Audited












      Revenues


      $                681


      $             2,877


      $                347


      $                534


      $             3,503












      Cost of revenues:











          Inventory impairment


      -


      -


      -


      -


      2,180

          Other cost of revenues


      336


      1,653


      206


      136


      1,914

      Total Cost of Revenues


      336


      1,653


      206


      136


      4,094












      Gross profit (loss)


      345


      1,224


      141


      398


      (591)












      Operating expenses:






















      Research and development, net


      2,938


      3,502


      1,374


      1,673


      6,262

      Sales and marketing


      708


      703


      319


      354


      1,359

      General and administrative


      1,984


      2,063


      889


      983


      4,021

      Other expenses (income)


      102


      (191)


      122


      -


      (205)












      Total operating expenses, net


      5,732


      6,077


      2,704


      3,010


      11,437












      Operating loss


      (5,387)


      (4,853)


      (2,563)


      (2,612)


      (12,028)












      Financing income


      2,304


      1,839


      1,140


      236


      2,618

      Financing expenses


      (4,045)


      (1,011)


      (168)


      (569)


      (1,841)












      Financing income (expenses), net


      (1,741)


      828


      972


      (333)


      777












      Share of loss from equity accounted investment


      (43)


      (66)


      -


      (64)


      (39)












      Loss before taxes on income


      (7,171)


      (4,091)


      (1,591)


      (3,009)


      (11,290)

      Taxes on income (tax benefit)


      -


      1


      -


      1


      1












      Loss from continuing operations


      (7,171)


      (4,092)


      (1,591)


      (3,010)


      (11,291)

      Income (loss) from discontinued operations, net


      (492)


      (3,579)


      (176)


      (1,671)


      3,464












      Loss


      $             (7,663)


      $             (7,671)


      $             (1,767)


      $             (4,681)


      $             (7,827)












      Attributable to:











      Equity holders of the Company


      $             (7,638)


      $             (7,050)


      $             (1,768)


      $             (4,462)


      $             (8,485)

      Non-controlling interests


      (25)


      (621)


      1


      (219)


      658














      $             (7,663)


      $             (7,671)


      $             (1,767)


      $             (4,681)


      $             (7,827)

      Basic and diluted loss per share from
      continuing operations, attributable to
      equity holders of the Company


      $             (0.63)


      $             (0.58)


      $             (0.13)


      $             (0.42)


      $             (1.41)























      Basic and diluted gain (loss) per share from
      discontinued operations, attributable to
      equity holders of the Company


      $             (0.04)


      $             (0.43)


      $             (0.01)


      $             (0.20)


      $             0.33












      Basic and diluted loss per share attributable to equity holders of the Company


      $              (0.67)


      $            (1.01)


      $             (0.14)


      $             (0.62)


      $             (1.08)


      Weighted average number of shares used in
      computing basic and diluted loss per share


      11,399,700


      7,012,031


      12,199,883


      7,225,862


      7,874,039


      (*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

      CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
      U.S. dollars in thousands 




       

      Six months ended
      June 30
      ,


       

      Three months ended
      June 30,


      Year ended
      December 31,




      2026


      2025  (*)


      2026


      2025 (*)


      2025 (*)



      Unaudited


      Audited


      Cash flows from operating activities






















      Loss from continuing operations


      $             (7,171)


      $             (4,092)


      $             (1,591)


      $    (3,010)


      $             (11,291)












      Adjustments to reconcile loss to net cash used in operating activities:


















      Adjustments to the profit or loss items:






















      Depreciation and amortization of property, plant and equipment
      and right-of-use-assets


      334


      507


      149


      245


      971

      Impairment of Property, Plant and Equipment


      116


      -


      116


      -


      -

      Inventory impairment


      -


      -


      -


      -


      2,180

      Share-based compensation


      93


      445


      93


      219


      728

      Remeasurement of Convertible SAFE


      -


      (345)


      -


      (345)


      (371)

      Net financing expenses (income)


      8


      156


      242


      147


      (28)

      Loss (gain) from sale of property, plant and equipment


      (14)


      (194)


      9


      (3)


      (205)

      Revaluation of government grants


      9


      -


      (11)


      -


      40

      Amortization of deferred expenses related to issuance of warrants


      1,716


      656


      -


      330


      1,323

      Remeasurement of pre-funded warrants and warrants


      (2,108)


      (1,318)


      (1,062)


      159


      (1,781)

      Expenses related to warrants inducement transaction


      2,095


      -


      -


      -


      -

      Share of loss of an associate


      43


      67


      -


      65


      39

      Taxes on income (tax benefit)


      -


      1


      (4)


      1


      (6)














      2,292


      (25)


      (468)


      818


      2,890

      Changes in asset and liability items:











      Decrease (increase) in trade receivables


      (67)


      (63)


      (98)


      1,467


      665

      Decrease (increase) in other receivables and prepaid expenses


      258


      1,287


      154


      (34)


      958

      Decrease (increase) in inventories


      117


      (601)


      82


      (154)


      (1,019)

      Increase (decrease) in trade payables


      (125)


      (164)


      42


      71


      (40)

      Increase (decrease) in employees and payroll accruals


      61


      (109)


      (5)


      64


      (494)

      Increase (decrease) in other payables


      (101)


      (298)


      (70)


      (152)


      (344)

      Increase (decrease) in deferred revenues and other advances


      (3)


      (351)


      (3)


      (196)


      (361)














      140


      (299)


      102


      1,066


      (635)












      CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
      U.S. dollars in thousands 




       

      Six months ended
      June 30,


       

      Three months ended
      June 30,


      Year ended
      December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)



      Unaudited


      Audited

      Cash received (paid) during the period for:






















      Interest received


      200


      176


      63


      81


      338

      Interest paid


      (84)


      (151)


      (44)


      (98)


      (256)

      Taxes paid


      (5)


      (11)


      10


      (11)


      (11)












      Net cash used in continuing operating activities


      (4,628)


      (4,402)


      (1,928)


      (1,154)


      (8,965)












      Net cash used in discontinued operating activities


      (300)


      (3,081)


      (46)


      (1,147)


      (4,537)












      Net cash used in operating activities


      (4,928)


      (7,483)


      (1,974)


      (2,301)


      (13,502)












      Cash flows from investing activities:

































      Purchase of property, plant and equipment


      (11)


      (122)


      (9)


      (2)


      (199)

      Proceeds from sale of property, plant and equipment


      112


      -


      89


      -


      78

      Proceeds from finance sub-lease asset


      33


      17


      12


      14


      52

      Withdrawal from (investment in) bank deposits, net


      -


      (1,001)


      2,928


      (1,001)


      (1)












      Net cash provided by (used in) continuing investing activities


      134


      (1,106)


      3,020


      (989)


      (70)












      Net cash provided by (used in) discontinued investing activities


      -


      (2,328)


      1,600


      -


      17,808












      Net cash provided by (used in) investing activities


      134


      (3,434)


      4,620


      (989)


      17,738












      CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
      U.S. dollars in thousands 




       

      Six months ended
      June 30
      ,


       

      Three months ended
      June 30,


      Year ended
      December 31,



      2026


      2025 (*)


      2026


      2025 (*)


      2025 (*)




      Unaudited


      Audited


      Cash flows from financing activities:
























      Proceeds from issuance of ordinary
      shares, net of issuance expenses


      805


      4,283


      805


      4,283


      4,283


      Proceeds from issuance of ordinary shares in warrant i
      nducement transaction, net of issuance expenses


      3,206


      -


      -


      -


      -


      Repayment of lease liability


      (213)


      (228)


      (117)


      (109)


      (423)


      Dividend paid by subsidiary


      (2,672)


      -


      (2,479)


      -


      -


      Repayment of convertible SAFE


      -


      -


      -


      -


      (10,000)


      Proceeds from government grants


      101


      -


      -


      -


      -


      Repayment of government grants


      (20)


      (122)


      (20)


      -


      (244)














      Net cash provided by (used in) continuing financing
      activities


      1,207


      3,933


      (1,811)


      4,174


      (6,384)














      Net cash provided by (used in) discontinued financing
      activities


      (50)


      57


      (25)


      (25)


      (218)














      Net cash provided by (used in) financing activities


      1,157


      3,990


      (1,836)


      4,149


      (6,602)














      Exchange rate differences - cash and cash equivalent
      balances


      (3)


      25


      (5)


      45


      21














      Increase (decrease) in cash and cash equivalents


      (3,640)


      (6,902)


      805


      904


      (2,345)














      Cash and cash equivalents, beginning of the period


      12,956


      15,301


      8,511


      7,495


      15,301


      Cash and cash equivalents presented in assets held
      for sale


      -


      (70)


      -


      (70)


      -














      Cash and cash equivalents, end of the period


      $            9,316


      $              8,329


      $              9,316


      $              8,329


      $              12,956














      Significant non-cash activities












      Acquisition of property, plant and equipment


      -


      $                   11


      -


      $                   11


      $                      2


      Right-of-use asset recognized with corresponding
      lease liability


      $                 15


      $                207


      -


      -


      $                   207


      Exercise of pre-funded warrants


      -


      $                389


      -


      $                 160


      $                   389


      Derecognition of property, plant and equipment under a
      finance lease


      -


      $                  13


      -


      -


      $                    13



      (*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

      SOURCE Evogene

      Modal title

      Also from this source

      Evogene Schedules Third Quarter 2026 Financial Results Release

      Evogene Schedules Third Quarter 2026 Financial Results Release

      Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules...

      Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

      Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

      Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules ...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Chemical

      Chemical

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.